Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Clin Cancer Res. 2016 Dec 30;23(13):3325–3333. doi: 10.1158/1078-0432.CCR-16-2809

Table 2.

PrediXcan replication of WFS1 association with hearing loss in an independent cohort of 18,620 patients from the Vanderbilt University BioVU Repository

Tissue WFS1 PVE [95% CI]a PheWAS Code Statisticb Pc Phenotype
Brain - Hypothalamus 0.23 [0.006, 0.83] 389 −3.4 0.00066 Hearing loss
Brain - Hypothalamus 0.23 [0.006, 0.83] 389.1 −3.3 0.0011 Sensorineural hearing loss
Artery 0.09 [0.003, 0.34] 389.1 −2.1 0.036 Sensorineural hearing loss
Brain - Nucleus accumbens (basal ganglia) 0.15 [0.006, 0.66] 389 −2.0 0.044 Hearing loss
a

PVE = proportion of variance in WFS1 expression explained by genetic effects (SNPs within 1 Mb) using Bayesian Sparse Linear Mixed Modeling (BSLMM), CI = credible interval

b

Negative statistic indicates decreased imputed expression is associated with increased susceptibility to phenotype

c

P values < 0.05 are shown. The Bonferroni significance level accounting for the 22 tests performed is P < 0.002.